Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Has Consensus Price Target of $46.38 According to Brokerages

Key Points

• Analysts are broadly positive: 12 analysts give DMRA a consensus “Buy” rating, with an average one-year price target of $46.38; seven rate it Buy and three Strong Buy.
• The company reported a quarterly loss of $0.40 per share, beating the $0.52 loss analysts expected. HC Wainwright lowered its 2026–27 earnings forecasts but maintained its Buy rating and $45 price target.
• CEO Jennifer Jarrett bought 12,500 shares at an average $20.23 each, while institutional investors own 14.2% of the stock; shares recently opened at $23.70.

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) have been assigned a consensus rating of "Buy" from the twelve analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $46.38.

Several brokerages have recently commented on DMRA. Weiss Ratings restated a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, September 29th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a report on Monday, August 24th. Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock from a "sell" rating to a "hold" rating in a research report on Sunday. Finally, HC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st.

More Damora Therapeutics, Inc. Common Stock News

Here are the key news stories impacting Damora Therapeutics, Inc. Common Stock this week:

• Positive Sentiment: Wall Street Zen raised its rating on DMRA to “Hold,” an improvement that may modestly bolster sentiment. Article: Damora Therapeutics Stock Bumped Up to Hold by Wall Street Zen
• Neutral Sentiment: Guggenheim initiated coverage, adding analyst attention; the headline does not specify its rating or price target. Article: Guggenheim Initiates Coverage on Damora Therapeutics
• Neutral Sentiment: DMRA crossed above its 50-day moving average, a potentially constructive technical signal, but the article also references an analyst downgrade. The downgrade’s details were not provided. Article: Damora Stock Crosses Above Fifty Day Moving Average After Analyst Downgrade
• Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including its FY2027 estimate from a loss of $1.59 to $1.70 per share. It retained a “Buy” rating and $45 price target, tempering the negative read-through. MarketBeat coverage of Damora Therapeutics

Insiders Place Their Bets

In other news, CEO Jennifer Jarrett acquired 12,500 shares of the firm's stock in a transaction on Friday, September 25th. The shares were purchased at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the transaction, the chief executive officer owned 512,500 shares of the company's stock, valued at approximately $10,367,875. This represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Braidwell LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. Seven Fleet Capital Management LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $7,398,000. Squarepoint Ops LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $303,000. Finally, Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $260,000. Institutional investors own 14.20% of the company's stock.

Damora Therapeutics, Inc. Common Stock Price Performance

Damora Therapeutics, Inc. Common Stock stock opened at $23.70 on Monday. The stock has a fifty day moving average price of $22.72 and a two-hundred day moving average price of $25.70. Damora Therapeutics, Inc. Common Stock has a 52-week low of $4.95 and a 52-week high of $38.33. The firm has a market capitalization of $1.47 billion, a P/E ratio of -7.03 and a beta of 1.52.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.12. On average, equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.